Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest.
The cis-stilbene, combretastatin A4 (CA4), is a potent microtubule targeting and vascular damaging agent. Despite promising results at the pre-clinical level and extensive clinical evaluation, CA4 has yet to be approved for therapeutic use. One impediment to the development of CA4 is an inherent con...
Main Authors: | Daniel Tarade, Dennis Ma, Christopher Pignanelli, Fadi Mansour, Daniel Simard, Sean van den Berg, James Gauld, James McNulty, Siyaram Pandey |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5333808?pdf=render |
Similar Items
-
Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells
by: McNulty James, et al.
Published: (2010-03-01) -
Combretastatin A-2 Synthetic Modifications
Published: (2011) -
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate.
by: Loadman, Paul M., et al.
Published: (2009) -
Mitotic arrest affects clustering of tumor cells
by: Julia Bonnet, et al.
Published: (2021-01-01) -
Mechanism of the butein-induced mitotic arrest and apoptosis
by: Huang, Yu-Tin, et al.
Published: (2011)